You are about to enter factorthinktank.com
This information is for European and UK healthcare professionals only
Are you a European or UK healthcare professional?
By selecting ‘No’, you will be diverted to www.sobi.com/en/haemophilia
Haemophilia B
Haemophilia B
Haemophilia B workstream
Paediatric haemophilia
workstream
Non-severe haemophilia
workstream
Joint health
workstream
Haemophilia B
workstream
Prof. Jan Astermark, MD, PhD
Lund University and Skåne University Hospital in Malmö, Sweden
Jan Astermark is a professor of clinical coagulation medicine at Lund University, Malmö, senior consultant and director of the Center for Thrombosis and Hemostasis in Malmö and assistant head of the Department of Translational Medicine in Malmö/Lund, Sweden. He is a specialist in haematology, coagulation disorders and internal medicine. He is a reviewer for haematology journals, and has published a number of original articles, review articles and book chapters in the field of haemophilia and coagulation disorders.
Prof. Cédric Hermans, MD, PhD, FRCP (Lon, Edin)
Division of Haematology, Saint-Luc University Hospital, Catholic University of Louvain, Brussels, Belgium
Cédric Hermans currently heads up the Division of Haematology, the Haemostasis and Thrombosis Unit and the Haemophilia Center of the Saint-Luc University Hospital in Brussels, Belgium, and is vice-dean of the Catholic University of Louvain Medical School, Brussels. His main research interests are around haemostasis and thrombosis, especially clinical studies on the treatment modalities and wide spectrum of complications of haemophilia in both developed and developing countries, as well as new anticoagulants and the management of thrombosis.
He has co-authored more than 330 original articles published in international journals and is a member of several scientific societies, international advisory boards and collaborative research projects. He is former president of the European Association for Haemophilia and Allied Disorders and is currently a member of the World Federation of Hemophilia board of directors, an associate member of the Belgian Royal Academy of Medicine, and editor-in-chief of Haemophilia.
Dr Peter Lenting, PhD
Laboratory for Haemostasis, Inflammation and Thrombosis, INSERM, and University of Paris-Saclay, Paris, France
Peter Lenting is director of research at the French National Institute for Health and Medical Research, Paris, France. His research activities are mainly focused on the biology of the factor VIII/von Willebrand factor complex and its related disorders, haemophilia A and von Willebrand disease.
He obtained his PhD at the medical faculty of the University of Amsterdam, Amsterdam, Netherlands, and was subsequently an associate professor of haematology at the University Medical Center in Utrecht, Netherlands, and Director of protein discovery at Crucell Holland (Leiden, Netherlands). He is a former elected member of the council of the International Society of Thrombosis and Haemostasis (ISTH) and former chair of the ISTH–World Health Organization Liaison Committee.
Prof. James O’Donnell, MB BCh BAO, BA, PhD, FRCPI, FRCPath
Irish Centre for Vascular Biology, School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland; National Coagulation Centre, St James’s Hospital, Dublin, Ireland; National Children’s Research Centre, Our Lady’s Children’s Hospital, Dublin, Ireland
James O’Donnell is a professor of vascular biology at the Royal College of Surgeons in Ireland; director of the Irish Centre for Vascular Biology; and a consultant haematologist at the National Coagulation Centre in Dublin, Ireland.
He received his medical degree from Trinity College, Dublin and completed haematology training at the Hammersmith and Royal Free Hospitals in London, UK. He is a fellow of both the Royal College of Physicians of Ireland and the Royal College of Pathologists (UK).
The haemostasis research laboratory led by him has focused on biochemistry relating to clinical bleeding and thrombosis. He has published more than 200 publications in high impact journals and has received over €12M in peer-reviewed grant funding awards.